

PROVECTUS PHARMACEUTICALS INC  
 Form 4/A  
 September 24, 2007

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 ADAMS DONALD E

(Last) (First) (Middle)

370 CRESTMONT DRIVE

(Street)

SAN LUIS OBISPO, CA 93401

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 PROVECTUS  
 PHARMACEUTICALS INC  
 [PVCT]

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 06/08/2006

4. If Amendment, Date Original Filed(Month/Day/Year)  
 09/24/2007

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
 \_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common stock	06/08/2006		C		518,657 (1)	A	\$ 0.737 5,006,250 D
Common stock	06/08/2006		C		28,727 (2)	A	\$ 0 5,034,977 D
Common stock	08/11/2006		S		15,000	D	\$ 1.13 5,019,977 D
Common stock	01/16/2007		S		6,000	D	\$ 1.22 5,013,977 D
Common stock	01/17/2007		S		2,000	D	\$ 1.23 5,011,977 D

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 4/A

Common stock	01/22/2007	S	6,000	D	\$ 1.2	5,005,977	D
Common stock	01/24/2007	S	1,500	D	\$ 1.2	5,004,477	D
Common stock	01/27/2007	P	<u>679,048</u> (3)	A	\$ 1.05	5,683,525	D
Common stock	01/31/2007	S	2,000	D	\$ 1.17	5,681,525	D
Common stock	02/06/2007	S	4,000	D	\$ 1.13	5,677,525	D
Common stock	02/07/2007	S	4,772	D	\$ 1.15	5,672,753	D
Common stock	02/13/2007	S	8,000	D	\$ 1.12	5,664,753	D
Common stock	02/20/2007	S	2,000	D	\$ 1.13	5,662,753	D
Common stock	02/23/2007	S	2,000	D	\$ 1.14	5,660,753	D
Common stock	03/02/2007	S	2,000	D	\$ 1.14	5,658,753	D
Common stock	03/07/2007	S	4,000	D	\$ 1.15	5,654,753	D
Common stock	03/19/2007	S	2,000	D	\$ 1.24	5,652,753	D
Common stock	03/21/2007	S	2,000	D	\$ 1.29	5,650,753	D
Common stock	04/03/2007	S	4,000	D	\$ 1.47	5,646,753	D
Common stock	04/11/2007	S	630	D	\$ 1.45	5,646,123	D
Common stock	09/04/2007	S	20,000	D	\$ 2.075	5,626,123	D
Common stock	09/05/2007	S	25,000	D	\$ 2.4	5,601,123	D
Common stock	09/06/2007	S	50,000	D	\$ 2.8	5,551,123	D
Common stock	09/06/2007	S	5,000	D	\$ 2.86	5,546,123	D
Common stock	09/06/2007	S	5,000	D	\$ 2.99	5,541,123	D
	09/06/2007	S	5,000	D	\$ 2.89	5,536,123	D

Common stock

Common stock 09/06/2007 S 5,000 D \$ 2.9 5,531,123 D

Common stock 09/06/2007 S 5,000 D \$ 2.98 5,526,123 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
\$382,250 8% Convertible Note	\$ 0.737	06/08/2006		C	547,384 (6)	11/26/2005 <sup>(4)</sup> 11/26/2006	Common Stock

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ADAMS DONALD E 370 CRESTMONT DRIVE SAN LUIS OBISPO, CA 93401			X	

## Signatures

/s/ DONALD E.  
ADAMS 09/24/2007

\*\*Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Issued upon the conversion of an 8% Convertible Note in the principal amount of \$382,250 reported on Form 3, dated March 29, 2006, at a conversion price of \$0.737 per share.
- (2) Shares received in satisfaction of accrued and unpaid interest of Convertible Note described above.
- (3) Shares purchased in a Private Placement under Regulation D of the Securities Act of 1933, as amended.
- (4) Convertible Note was convertible into shares of Common Stock at any time at the sole discretion of the Reporting Person.  
Does not include (i) 1,116,667 shares of Common Stock issuable upon the exercise of a warrant at a purchase price of \$0.935 per share and expiring on December 31, 2010 and (ii) 533,333 shares of Common Stock issuable upon the exercise of a warrant at a purchase price of \$0.99 per share and expiring on March 30, 2010.
- (6) Consists of (i) 518,657 shares of Common Stock issued upon the conversion of the principal amount of the Convertible Note and (ii) 28,727 shares of Common Stock issued in satisfaction of accrued and unpaid interest on the Convertible Note.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.